Abstract 337P
Background
T and NK-cell lymphoma represents approximately 10 to 15% of all non-Hodgkin’s lymphoma worldwide. However, the epidemiology of underlying subtypes varies geographically. As such, we aim to investigate disease patterns, patient demographics and survival outcomes in a multiethnic cohort from Singapore.
Methods
We performed a retrospective analysis on various histological subtypes of T and NK-cell lymphoma diagnosed from 2004 to 2022 (n=325) at the National Cancer Centre Singapore. Clinico-demographic data were collated across major ethnic groups (Chinese, Malay and Indian) and pre-defined age groups (<40, 40-65, and >65 years). Overall survival was estimated using the Kaplan-Meier method.
Results
In our study cohort, the median age was 55 years (range, 15-88), with a male predominance (61.2%). Major ethnic groups include Chinese (72.0%), followed by Malays (10.5%) and Indians (4.6%). In terms of age at diagnosis, the majority presented between ages 40 to 65 years (50.8%) in comparison to other age groups (<40 years, 24.0%) and (>65 years, 25.2%). The most common histological subtypes include angioimmunoblastic T-cell lymphoma/peripheral T-cell lymphoma T-follicular helper phenotype (AITL/PTCL-TFH) (38.8%), natural killer/T-cell lymphoma (NKTCL) (17.2%), and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) (12.6%). In analysis by age groups, AITL/PTCL-TFH was the dominant diagnosis. The next most common diagnosis was NKTCL for patients above 65 years, and was PTCL-NOS in patients under 40 years. Further analysis of ethnic distribution amongst these common subtypes revealed a similar trend, though interestingly, NKTCL was not observed amongst the Indian subgroup. In the whole cohort, the median overall survival was 21.4 years with a 5-year OS of 75.6%. 5-year OS was significantly worse for PTCL-NOS as compared to AITL/PTCL-TFH or NKTCL (62.5% vs 79.2% and 78.5%, respectively; log-rank p=0.0225). Age at diagnosis, disease stage and IPI risk groups were significantly prognostic, but not ethnic groups and sex.
Conclusions
Through this analysis we identified unique demographic and survival patterns in T and NK-cell lymphoma within our local population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tanoto Foundation Professorship in Medical Oncology New Century Foundation Limited Ling Foundation Singapore Ministry of Health’s National Medical Research Council Research Transition Award (TA21jun-0005) and Large Collaborative Grant (OFLCG18May-0028).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract